BackKeros Therapeutics Overview
Keros Therapeutics Inc

Keros Therapeutics Target Price

Analysts' average 12-month price target for Keros Therapeutics is $20.

Get informed when a big investor buys or sells

+ Follow

Share Price

$11.36

Average Target Price

$20.3379% upside

3 analysts in the last 4 months

High: $23 | Low: $18

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-04Wells FargoBenjamin Burnett$1858.5% upsideOpen
2026-08-04H.C. WainwrightAndrew Fein$2076.1% upsideOpen
2026-08-04Leerink Partners$23102.5% upsideOpen
2024-11-05JefferiesKelly Shi$107841.9% upsideOpen
2024-11-05Truist FinancialSrikripa Devarakonda$100780.3% upsideOpen
2024-09-23GuggenheimVamil Divan$96745.1% upsideOpen
2024-06-18Piper SandlerJoseph Catanzaro$105824.3% upsideOpen
2022-12-13BTIG$105824.3% upsideOpen
2022-07-27BTIGJulian Harrison$80604.2% upsideOpen
2022-05-18Piper SandlerJoseph Catanzaro$120956.3% upsideOpen

Keros Therapeutics (KROS) FAQ

Keros Therapeutics's target price stands at $20. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $20 for KROS implies 79.0% upside versus today's price ($11.36). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Keros Therapeutics's target price evolved across reporting periods, while the comparison chart places KROS next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Keros Therapeutics's reading of $20 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.